Digital Biomarkers Market by Type, Therapy, Application, End User - Global Forecast to 2031

1.1 Study Objectives
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Segmentation & Regional Scope
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.4 Currency Considered
1.5 Limitations
1.6 Stakeholders

2.1 Key Insights and Market Highlights
2.2 Key Market Participants: Share Insights and Strategic Developments
2.3 Disruptive Trends Shaping the Market
2.4 High-Growth Segments & Emerging Frontiers
2.5 Snapshot: Global Market Size, Growth Rate, and Forecast

3.1 Digital Biomarkers Market Overview
3.2 Digital Biomarkers Market, by Application & Region
3.3 Digital Biomarkers Market: Geographic Snapshot

4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Expansion of Smartphones, Wearables, and Connected Health Ecosystems
4.2.1.2 Expansion of Decentralized and Remote Clinical Trials
4.2.1.3 Rising Prevalence of Chronic Diseases That Require Continuous Monitoring
4.2.1.4 Advancements in AI and Digital Health Analytics
4.2.2 Restraints
4.2.2.1 Data Privacy and Cybersecurity Concerns
4.2.2.2 Limited Digital Literacy and Technology Access Among Patients
4.2.3 Opportunities
4.2.3.1 Increasing Use in Drug Development and Clinical Trial Endpoints
4.2.3.2 Growth of Precision Medicine and Personalized Healthcare
4.2.3.3 Emerging Applications in Neurological and Mental Health Monitoring
4.2.4 Challenges
4.2.4.1 Lack of Standardized Validation Frameworks for Digital Biomarkers
4.2.4.2 Regulatory Uncertainty Around Digital Endpoints and Biomarker Validation
4.3 Unmet Needs and White Spaces
4.4 Interconnected Markets and Cross-Sector Opportunities
4.5 Strategic Moves by Tier-1/2/3 Players

5.1 Porter's Five Forces Analysis
5.1.1 Bargaining Power of Suppliers (Moderate)
5.1.2 Bargaining Power of Buyers (High)
5.1.3 Threat of Substitutes (Moderate to High)
5.1.4 Threat of New Entrants (Moderate)
5.1.5 Intensity of Competitive Rivalry (High)
5.2 Macroeconomic Indicators
5.2.1 Introduction
5.2.2 GDP Trends and Forecast
5.2.3 Trends in Global Healthcare IT Industry
5.3 Supply Chain Analysis
5.4 Ecosystem Analysis
5.5 Pricing Analysis
5.5.1 Indicative Price for Digital Biomarkers, by Key Player (2025)
5.5.2 Indicative Price for Digital Biomarkers, by Region (2025)
5.6 Key Conferences and Events, 2026-2027
5.7 Trends/Disruptions Impacting Customer Business
5.8 Investment and Funding Scenario
5.9 Case Study Analysis
5.10 Impact of 2025 US Tariff on Digital Biomarkers Market
5.10.1 Introduction
5.10.2 Key Tariff Rates
5.10.3 Price Impact Analysis
5.10.4 Impact on Country/Region
5.10.4.1 US
5.10.4.2 Europe
5.10.4.3 Asia-Pacific
5.10.5 Impact on End-users
5.10.5.1 Pharmaceutical and Biotechnology Companies
5.10.5.2 Contract Research Organizations
5.10.5.3 Hospitals and Specialty Clinics
5.10.5.4 Others (Research Institutes, Etc.)

6.1 Introduction
6.2 Decision-Making Process
6.3 Key Stakeholders and Buying Evaluation Criteria
6.3.1 Key Stakeholders in Buying Process
6.3.2 Buying Criteria
6.4 Adoption Barriers & Internal Challenges
6.5 Unmet Needs from Various End-use Industries
6.5.1 Unmet Needs
6.5.2 End-user Expectations
6.6 Market Profitability

7.1 Regional Regulations and Compliance
7.1.1 Regulatory Bodies, Government Agencies, & Other Organizations
7.1.2 Regulatory Framework
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia-Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 Industry Standards

8.1 Key Emerging Technologies
8.1.1 Wearable Sensor Technologies
8.1.2 Artificial Intelligence and Machine Learning Analytics
8.1.3 Mobile Health (Mhealth) Platforms and Smartphone Sensors
8.2 Complementary Technologies
8.2.1 Internet of Medical Things (Iomt)
8.2.2 Telehealth and Remote Patient Monitoring
8.3 Adjacent Technologies
8.3.1 Digital Therapeutics
8.3.2 Digital Pathology and Imaging AI
8.4 Technology/Product Roadmap
8.5 Patent Analysis
8.5.1 Patent Publication Trends in Digital Biomarkers Market
8.5.2 Insights: Jurisdiction and Top Applicant Analysis
8.6 Future Applications
8.6.1 AI-Enabled Intelligent Screening and Interpretation
8.6.2 Continuous and Predictive Health Monitoring Applications
8.6.3 Decentralized, Remote, and Real-World Data Ecosystems
8.7 Impact of AI/Gen AI on Digital Biomarkers Market
8.7.1 Introduction
8.7.2 Market Potential of AI/Gen AI in Digital Biomarkers Market
8.7.3 Case Studies Related to AI/Gen AI Implementation
8.7.3.1 Early Alzheimer's Detection Using Mobile-based Cognitive Assessment Platforms
8.7.4 Impact of AI/Gen AI on Interconnected and Adjacent Ecosystems
8.7.4.1 Digital Health Market
8.7.4.2 Remote Patient Monitoring Market
8.7.4.3 Telehealth & Telemedicine Market
8.7.5 User Readiness and Impact Assessment
8.7.5.1 User Readiness
8.7.5.1.1 User A: Pharmaceutical & Biotechnology Companies
8.7.5.1.2 User B: Contract Research Organizations (Cros)
8.7.5.2 Impact Assessment
8.7.5.2.1 User A: Pharmaceutical & Biotechnology Companies
8.7.5.2.1.1 Implementation
8.7.5.2.1.2 Impact
8.7.5.2.2 User B: Contract Research Organizations
8.7.5.2.2.1 Implementation
8.7.5.2.2.2 Impact

9.1 Introduction
9.2 Physiological Biomarkers
9.2.1 Segment Leads Market Adoption Through Clinical Validation and AI-Driven Analytics
9.3 Idiosyncratic Biomarkers
9.3.1 Precision Medicine Driven Through Personalized, Individual-Level Data Insights
9.4 Cognitive Biomarkers
9.4.1 Enable Scalable and Objective Measurement of Neurological Function Through Advanced Analytics
9.5 Vocal Biomarkers
9.5.1 AI-Powered Voice Analysis Enables Scalable Mental Health Monitoring
9.6 Other Biomarkers

10.1 Introduction
10.2 Cardiovascular
10.2.1 Atherosclerotic Cardiovascular Disease/Secondary Prevention
10.2.1.1 Continuous Risk Monitoring and Predictive Insights in Cardiovascular Disease Management - Key Driver
10.2.2 Heart Failure (Hfref & Hfpef)
10.2.2.1 Demand Driven by Advanced Early Detection and Remote Monitoring in Heart Failure Management
10.2.3 Hypertension
10.2.3.1 Transforming Blood Pressure Assessment from Episodic to Continuous Monitoring
10.2.4 Atrial Fibrillation/Stroke Prevention
10.2.4.1 Unlocking Subclinical Af Identification Via Long-Duration Rhythm Analytics
10.2.5 Pulmonary Hypertension
10.2.5.1 Advancement of Functional Endpoint Measurement Beyond Traditional Walk Tests to Boost Growth
10.2.6 Structural Heart Disease/Interventional Cardiology
10.2.6.1 Remote Post-Procedural Surveillance in Structural Heart Interventions to Drive Segment
10.3 Oncology
10.3.1 Solid Tumors
10.3.1.1 Breast Cancer
10.3.1.1.1 Segment Driven by Enhanced Tumor Characterization Through AI-Driven Imaging and Pathology Analytics
10.3.1.2 Lung Cancer
10.3.1.2.1 Enhanced Immunotherapy Response Prediction Using Imaging Biomarkers to Boost Growth
10.3.1.3 Prostate Cancer
10.3.1.3.1 Segment Growth Propelled by Reduced Variability in Cancer Grading with Quantitative Digital Pathology
10.3.1.4 Colorectal Cancer
10.3.1.4.1 Enhanced Gastrointestinal Oncology Trials with Decentralized Functional Endpoints - Major Driver
10.3.1.5 Brain Tumor
10.3.1.5.1 Enhanced Tumor Monitoring with Advanced MRI and Volumetric Analytics
10.3.1.6 Other Solid Tumors
10.3.1.6.1 Extension of Digital Biomarker Utility Across Rare and Heterogeneous Tumor Types to Drive Segment
10.3.2 Hematologic Malignancies
10.3.2.1 Leukemia
10.3.2.1.1 Enhanced Mrd Detection and Quantification Through AI-Driven Analytics to Boost Market
10.3.2.2 Lymphoma
10.3.2.2.1 Capturing Immune Response Dynamics with Continuous Digital Monitoring - Key Benefit
10.3.2.3 Multiple Myeloma
10.3.2.3.1 Segment Growth Driven by Enhanced Disease Burden Assessment with Integrated Imaging and Pathology Analytics
10.3.2.4 Other Hematologic Malignancies
10.3.2.4.1 High-Sensitivity Endpoint Generation in Small Patient Populations to Boost Market
10.4 Diabetes
10.4.1 Continuous Monitoring Platforms Expanding into Holistic Cardiometabolic Risk Prediction
10.5 Mental Health & Behavioral Health
10.5.1 Passive Behavioral and Voice Data Enable Scalable Objective Condition Monitoring
10.6 Respiratory Disorders
10.6.1 Early Exacerbation Detection Through Continuous Monitoring Reduces Hospitalizations and Costs
10.7 Lifestyle & Wellness Improvement
10.7.1 Expanding Preventive Health Through Continuous Behavioral Data Insights
10.8 Neurology
10.8.1 Regulatory Validation of Digital Endpoints to Accelerate Early Detection and Trial Adoption
10.9 Musculoskeletal Disorders/Pain Management
10.9.1 Employer-Backed Digital Care and Motion Tracking to Drive Scalable Rehabilitation Solutions
10.10 Women's Health & Reproductive Health
10.10.1 Addressing Unmet Needs Through Data-Driven Women's Health Insights
10.11 Other Diseases
10.11.1 Expanding Use Cases to Drive Adoption Across Chronic and Underserved Conditions

11.1 Introduction
11.2 Clinical Research
11.2.1 Phase II
11.2.1.1 Critical Role in Early-Stage Validation and Risk Reduction in Clinical Development
11.2.2 Phase III
11.2.2.1 Regulatory-Grade Endpoint Validation Drives High-Stakes Clinical Trial Adoption
11.2.3 Phase IV
11.2.3.1 Real-World Evidence Demand Drives Scalable Continuous Monitoring and Reimbursement Adoption
11.3 Clinical Care
11.3.1 Rising Chronic Disease Burden Driving Shift to Continuous Proactive Care

12.1 Introduction
12.2 Pharmaceutical & Biotechnology Companies
12.2.1 Clinical Trial Driven Efficiency Through High-Impact Digital Endpoints
12.3 Contract Research Organizations
12.3.1 End-To-End Digital Trial Execution Enabled Through Advanced Analytics
12.4 Hospitals & Specialty Clinics
12.4.1 Enhanced Clinical Outcomes with Real-Time, Data-Driven Care Delivery
12.5 Other End-users
12.5.1 Public Funding and Real-World Data Initiatives Accelerate Ecosystem-Wide Adoption

13.1 Introduction
13.2 North America
13.2.1 Macroeconomic Outlook for North America
13.2.2 US
13.2.2.1 Regulatory Advancements and Pharma-Tech Convergence Drive Market Growth
13.2.3 Canada
13.2.3.1 Increasing Integration of AI-Driven Screening and Remote Monitoring to Drive Market
13.3 Europe
13.3.1 Macroeconomic Outlook for Europe
13.3.2 Germany
13.3.2.1 Strong Clinical Trial Ecosystem and Progressive Digital Health Regulation to Drive Market
13.3.3 France
13.3.3.1 Strong Clinical Trial Base and Evidence-Driven Regulatory Pathways to Drive Market
13.3.4 Uk
13.3.4.1 Strong Nhs Data Infrastructure and Push for Data-Enabled Clinical Trials to Drive Market
13.3.5 Italy
13.3.5.1 Strong Clinical Research Activity and Oncology-Driven Demand to Shape Market Growth
13.3.6 Spain
13.3.6.1 Strong Clinical Trial Leadership and High Domestic Research Concentration to Drive Market
13.3.7 Rest of Europe
13.4 Latin America
13.4.1 Macroeconomic Outlook for Latin America
13.4.2 Brazil
13.4.2.1 Expanding Digital Health Ecosystem and Regulatory Reforms to Drive Digital Biomarkers Adoption
13.4.3 Mexico
13.4.3.1 Growing Clinical Trial Participation and Digital Transformation to Drive Digital Biomarkers Adoption
13.4.4 Rest of Latin America
13.5 Asia-Pacific
13.5.1 Asia-Pacific: Clinical Trial Initiations in 2014 and 2024
13.5.2 Macroeconomic Outlook for Asia-Pacific
13.5.3 China
13.5.3.1 Expanding Clinical Trial Leadership and Advancing Digital Health Ecosystem to Drive Market
13.5.4 Japan
13.5.4.1 Declining Clinical Trial Activity Despite Strong Legacy Position to Impact Market
13.5.5 India
13.5.5.1 Rapid Clinical Trial Growth, Cost Advantages, and Regulatory Reforms to Drive Market
13.5.6 Australia
13.5.6.1 Strong Early-Phase Trial Capabilities and Advanced Research Infrastructure to Drive Market
13.5.7 South Korea
13.5.7.1 Steady Clinical Trial Growth and Strong Innovation Ecosystem to Drive Market
13.5.8 Rest of Asia-Pacific
13.6 Middle East & Africa
13.6.1 Macroeconomic Outlook for Middle East & Africa
13.6.2 Gcc Countries
13.6.2.1 Strong Digital Health Transformation and Growing Clinical Research Activity to Drive Adoption
13.6.3 Saudi Arabia
13.6.3.1 Expanding Clinical Research Activity and Government-Led Initiatives to Drive Market
13.6.4 Uae
13.6.4.1 Advancing Digital Health Innovation and Strategic Collaborations - Key Growth Drivers
13.6.5 Other Gcc Countries
13.6.5.1 Regulatory Initiatives, National Health Visions, and Digital Health Infrastructure Boost Market Growth
13.6.6 South Africa
13.6.6.1 Leading Clinical Research Hub in Africa with Strong Infrastructure
13.6.7 Rest of Middle East & Africa

14.1 Overview
14.2 Key Player Strategies/Right to Win
14.2.1 Overview of Strategies Adopted by Key Players in Digital Biomarkers Market
14.3 Revenue Share Analysis of the Top Market Players
14.4 Market Share Analysis, 2025
14.5 Brand Comparison
14.6 Company Valuation & Financial Metrics
14.6.1 Financial Metrics
14.6.2 Company Valuation
14.7 Company Evaluation Matrix
14.7.1 Stars
14.7.2 Emerging Leaders
14.7.3 Pervasive Players
14.7.4 Participants
14.7.5 Company Footprint: Key Players, 2025
14.7.5.1 Company Footprint
14.7.5.2 Region Footprint
14.7.5.3 Type Footprint
14.7.5.4 Therapeutic Area Footprint
14.7.5.5 Application Footprint
14.7.5.6 End-user Footprint
14.8 Company Evaluation Matrix: Startups/SMEs, 2025
14.8.1 Progressive Companies
14.8.2 Responsive Companies
14.8.3 Dynamic Companies
14.8.4 Starting Blocks
14.8.5 Competitive Benchmarking: Startups/SMEs, 2024
14.8.5.1 Detailed List of Key Startups/SMEs
14.8.5.2 Competitive Benchmarking of Startups/SMEs
14.9 Competitive Scenario
14.9.1 Product/Service Launches & Approvals
14.9.2 Deals
14.9.3 Other Developments

15.1 Key Players
15.1.1 Ixico PLC
15.1.1.1 Business Overview
15.1.1.2 Products Offered
15.1.1.3 Recent Developments
15.1.1.3.1 Product Launches/Approvals
15.1.1.3.2 Deals
15.1.1.4 Analyst's View
15.1.1.4.1 Key Strengths
15.1.1.4.2 Strategic Choices
15.1.1.4.3 Weaknesses and Competitive Threats
15.1.2 Ametris, LLC
15.1.2.1 Business Overview
15.1.2.2 Products Offered
15.1.2.3 Recent Developments
15.1.2.3.1 Product Launches/Enhancements
15.1.2.3.2 Deals
15.1.2.4 Analyst's View
15.1.2.4.1 Key Strengths
15.1.2.4.2 Strategic Choices
15.1.2.4.3 Weaknesses and Competitive Threats
15.1.3 Empatica Inc.
15.1.3.1 Business Overview
15.1.3.2 Products/Solutions Offered
15.1.3.3 Recent Developments
15.1.3.3.1 Product Launches/Approvals
15.1.3.3.2 Deals
15.1.3.4 Analyst's View
15.1.3.4.1 Key Strengths
15.1.3.4.2 Strategic Choices
15.1.3.4.3 Weaknesses and Competitive Threats
15.1.4 Alivecor, Inc.
15.1.4.1 Business Overview
15.1.4.2 Products Offered
15.1.4.3 Recent Developments
15.1.4.3.1 Product Launches/Approvals
15.1.4.3.2 Deals
15.1.4.4 Analyst's View
15.1.4.4.1 Key Strengths
15.1.4.4.2 Strategic Choices
15.1.4.4.3 Weaknesses and Competitive Threats
15.1.5 Conneqt Health
15.1.5.1 Business Overview
15.1.5.2 Products Offered
15.1.5.3 Recent Developments
15.1.5.3.1 Product Enhancements/Approvals
15.1.5.4 Analyst's View
15.1.5.4.1 Key Strengths
15.1.5.4.2 Strategic Choices
15.1.5.4.3 Weaknesses and Competitive Threats
15.1.6 Vivosense
15.1.6.1 Business Overview
15.1.6.2 Products Offered
15.1.6.2.1 Other Developments
15.1.7 Biosensics
15.1.7.1 Business Overview
15.1.7.2 Products Offered
15.1.7.3 Recent Developments
15.1.7.3.1 Product Launches/Approvals
15.1.7.3.2 Deals
15.1.8 Lunit Inc.
15.1.8.1 Business Overview
15.1.8.2 Products Offered
15.1.8.3 Recent Developments
15.1.8.3.1 Product Launches/Approvals
15.1.8.3.2 Deals
15.1.9 Akili, Inc.
15.1.9.1 Business Overview
15.1.9.2 Products Offered
15.1.9.3 Recent Developments
15.1.9.3.1 Deals
15.1.10 Quibim
15.1.10.1 Business Overview
15.1.10.2 Products Offered
15.1.10.3 Recent Developments
15.1.10.3.1 Product Launches/Approvals/Enhancements
15.1.10.3.2 Deals
15.1.11 Clario
15.1.11.1 Business Overview
15.1.11.2 Products Offered
15.1.11.3 Recent Developments
15.1.11.3.1 Deals
15.1.12 Proscia Inc.
15.1.12.1 Business Overview
15.1.12.2 Products Offered
15.1.12.3 Recent Developments
15.1.12.3.1 Product Launches/Approvals
15.1.12.3.2 Deals
15.1.13 Koneksa Health
15.1.13.1 Business Overview
15.1.13.2 Products Offered
15.1.13.3 Recent Developments
15.1.13.3.1 Product Launches
15.1.13.3.2 Deals
15.1.14 Linus Health
15.1.14.1 Business Overview
15.1.14.2 Products Offered
15.1.14.3 Recent Developments
15.1.14.3.1 Product Launches/Approvals
15.1.14.3.2 Deals
15.2 Other Players
15.2.1 Sonde Health, Inc.
15.2.2 Altoida
15.2.3 Imvaria Inc.
15.2.4 Cumulus Neuroscience Limited
15.2.5 Delve Health
15.2.6 Feel Therapeutics
15.2.7 Nanowear Inc.
15.2.8 Exosystems
15.2.9 Cardiosignal
15.2.10 Imagene AI Ltd.
15.2.11 Neurotrack Technologies, Inc.

16.1 Research Approach
16.1.1 Secondary Research
16.1.1.1 Key Data from Secondary Sources
16.1.2 Primary Research
16.1.2.1 Primary Sources
16.1.2.2 Key Data from Primary Sources
16.1.2.3 Breakdown of Primaries
16.1.2.4 Insights from Primary Experts
16.2 Research Methodology Design
16.3 Market Size Estimation
16.4 Market Breakdown Data Triangulation
16.5 Market Share Estimation
16.6 Study Assumptions
16.7 Research Limitations
16.7.1 Methodology-Related Limitations
16.8 Risk Assessment

17.1 Discussion Guide
17.2 Knowledgestore: The Subscription Portal
17.3 Customization Options

Table 1 USD Exchange Rates
Table 2 Digital Biomarkers Market: Porter's Five Forces Analysis
Table 3 Digital Biomarkers Market: Role in Ecosystem
Table 4 Indicative Price for Digital Biomarkers, by Key Player (2025)
Table 5 Indicative Price for Digital Biomarkers, by Region (2025)
Table 6 Case 1: Empatica - Integration of Digital Biomarkers into High-Altitude Endocrinology Research (Apex 7 Hicort Study)
Table 7 Case 2: Vivosense - Digital Biomarkers for Ptsd Monitoring and Assessment
Table 8 Case 3: Delve Health - Improved Data Integrity in Clinical Trials with Digital Biomarkers
Table 9 US Adjusted Reciprocal Tariff Rates
Table 10 Influence of Stakeholders on Buying Process of Top Three End-users (%)
Table 11 Key Buying Criteria for Top Three End-users
Table 12 Unmet Needs in Digital Biomarkers Market
Table 13 End-user Expectations in Digital Biomarkers Market
Table 14 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 15 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 16 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 17 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 18 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 19 Regulatory Scenario in North America
Table 20 Regulatory Scenario in Europe
Table 21 Regulatory Scenario in Asia-Pacific
Table 22 Regulatory Scenario in Latin America
Table 23 Regulatory Scenario in Middle East & Africa
Table 24 Digital Biomarkers Market: Jurisdiction Analysis of Top Applicant Countries
Table 25 Digital Biomarkers Market: List of Patents/Patent Applications
Table 26 Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 27 Physiological Biomarkers: Major Players and Offerings
Table 28 Physiological Biomarkers: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 29 Idiosyncratic Biomarkers: Major Players and Offerings
Table 30 Idiosyncratic Biomarkers: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 31 Cognitive Biomarkers: Major Players and Offerings
Table 32 Cognitive Biomarkers: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 33 Vocal Biomarkers: Major Players and Offerings
Table 34 Vocal Biomarkers: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 35 Other Biomarkers: Major Players and Offerings
Table 36 Other Biomarkers: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 37 Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 38 Cardiovascular: Major Players and Offerings
Table 39 Cardiovascular: Digital Biomarkers Market, by Condition, 2024-2031 (USD Million)
Table 40 Cardiovascular: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 41 Ascvd/Secondary Prevention: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 42 Heart Failure (Hfref & Hfpef): Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 43 Hypertension: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 44 Atrial Fibrillation/Stroke Prevention: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 45 Pulmonary Hypertension: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 46 Structural Heart Disease/Interventional Cardiology: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 47 Oncology: Major Players and Offerings
Table 48 Oncology: Digital Biomarkers Market, by Tumor Type, 2024-2031 (USD Million)
Table 49 Oncology: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 50 Solid Tumors: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 51 Solid Tumors: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 52 Breast Cancer: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 53 Lung Cancer: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 54 Prostate Cancer: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 55 Colorectal Cancer: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 56 Brain Tumor: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 57 Other Solid Tumors: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 58 Hematologic Malignancies: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 59 Hematologic Malignancies: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 60 Leukemia: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 61 Lymphoma: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 62 Multiple Myeloma: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 63 Other Hematologic Malignancies: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 64 Diabetes: Major Players and Offerings
Table 65 Diabetes: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 66 Mental Health & Behavioral Health: Major Players and Offerings
Table 67 Mental Health & Behavioral Health: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 68 Respiratory Disorders: Major Players and Offerings
Table 69 Respiratory Disorders: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 70 Lifestyle & Wellness Improvement: Major Players and Offerings
Table 71 Lifestyle & Wellness Improvement: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 72 Neurology: Major Players and Offerings
Table 73 Neurology: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 74 Musculoskeletal Disorders/Pain Management: Major Players and Offerings
Table 75 Musculoskeletal Disorders/Pain Management: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 76 Women's Health & Reproductive Health: Major Players and Offerings
Table 77 Women's Health & Reproductive Health: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 78 Other Diseases: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 79 Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 80 Clinical Research: Digital Biomarkers Market, by Phase, 2024-2031 (USD Million)
Table 81 Clinical Research: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 82 Phase II Clinical Research: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 83 Phase III Clinical Research: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 84 Phase IV Clinical Research: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 85 Clinical Care: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 86 Digital Biomarker Market, by End-user, 2024-2031 (USD Million)
Table 87 Pharmaceutical & Biotechnology Companies: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 88 Contract Research Organizations: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 89 Hospitals & Specialty Clinics: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 90 Other End-users: Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 91 Digital Biomarkers Market, by Region, 2024-2031 (USD Million)
Table 92 North America: Digital Biomarkers Market, by Country, 2024-2031 (USD Million)
Table 93 North America: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 94 North America: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 95 North America: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 96 North America: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 97 North America: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 98 North America: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 99 North America: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 100 North America: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 101 North America: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 102 US: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 103 US: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 104 US: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 105 US: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 106 US: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 107 US: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 108 US: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 109 US: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 110 US: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 111 Canada: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 112 Canada: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 113 Canada: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 114 Canada: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 115 Canada: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 116 Canada: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 117 Canada: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 118 Canada: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 119 Canada: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 120 Europe: Digital Biomarkers Market, by Country, 2024-2031 (USD Million)
Table 121 Europe: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 122 Europe: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 123 Europe: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 124 Europe: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 125 Europe: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 126 Europe: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 127 Europe: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 128 Europe: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 129 Europe: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 130 Germany: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 131 Germany: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 132 Germany: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 133 Germany: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 134 Germany: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 135 Germany: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 136 Germany: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 137 Germany: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 138 Germany: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 139 France: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 140 France: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 141 France: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 142 France: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 143 France: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 144 France: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 145 France: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 146 France: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 147 France: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 148 Uk: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 149 Uk: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 150 Uk: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 151 Uk: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 152 Uk: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 153 Uk: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 154 Uk: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 155 Uk: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 156 Uk: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 157 Italy: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 158 Italy: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 159 Italy: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 160 Italy: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 161 Italy: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 162 Italy: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 163 Italy: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 164 Italy: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 165 Italy: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 166 Spain: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 167 Spain: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 168 Spain: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 169 Spain: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 170 Spain: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 171 Spain: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 172 Spain: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 173 Spain: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 174 Spain: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 175 Rest of Europe: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 176 Rest of Europe: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 177 Rest of Europe: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 178 Rest of Europe: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 179 Rest of Europe: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 180 Rest of Europe: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 181 Rest of Europe: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 182 Rest of Europe: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 183 Rest of Europe: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 184 Latin America: Digital Biomarkers Market, by Country, 2024-2031 (USD Million)
Table 185 Latin America: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 186 Latin America: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 187 Latin America: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 188 Latin America: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 189 Latin America: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 190 Latin America: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 191 Latin America: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 192 Latin America: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 193 Latin America: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 194 Brazil: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 195 Brazil: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 196 Brazil: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 197 Brazil: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 198 Brazil: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 199 Brazil: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 200 Brazil: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 201 Brazil: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 202 Brazil: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 203 Mexico: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 204 Mexico: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 205 Mexico: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 206 Mexico: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 207 Mexico: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 208 Mexico: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 209 Mexico: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 210 Mexico: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 211 Mexico: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 212 Rest of Latin America: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 213 Rest of Latin America: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 214 Rest of Latin America: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 215 Rest of Latin America: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 216 Rest of Latin America: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 217 Rest of Latin America: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 218 Rest of Latin America: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 219 Rest of Latin America: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 220 Rest of Latin America: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 221 Asia-Pacific: Digital Biomarkers Market, by Country, 2024-2031 (USD Million)
Table 222 Asia-Pacific: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 223 Asia-Pacific: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 224 Asia-Pacific: Digital Biomarkers Market, for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 225 Asia-Pacific: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 226 Asia-Pacific: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 227 Asia-Pacific: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 228 Asia-Pacific: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 229 Asia-Pacific: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 230 Asia-Pacific: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 231 China: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 232 China: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 233 China: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 234 China: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 235 China: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 236 China: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 237 China: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 238 China: Digital Biomarkers Market for Clinical Research, by Type, 2024-2031 (USD Million)
Table 239 China: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 240 Japan: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 241 Japan: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 242 Japan: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 243 Japan: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 244 Japan: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 245 Japan: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 246 Japan: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 247 Japan: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 248 Japan: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 249 India: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 250 India: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 251 India: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 252 India: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 253 India: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 254 India: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 255 India: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 256 India: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 257 India: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 258 Australia: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 259 Australia: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 260 Australia: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 261 Australia: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 262 Australia: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 263 Australia: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 264 Australia: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 265 Australia: Digital Biomarkers Market for Clinical Research, by Type, 2024-2031 (USD Million)
Table 266 Australia: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 267 South Korea: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 268 South Korea: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 269 South Korea: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 270 South Korea: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 271 South Korea: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 272 South Korea: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 273 South Korea: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 274 South Korea: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 275 South Korea: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 276 Rest of Asia-Pacific: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 277 Rest of Asia-Pacific: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 278 Rest of Asia-Pacific: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 279 Rest of Asia-Pacific: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 280 Rest of Asia-Pacific: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 281 Rest of Asia-Pacific: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 282 Rest of Asia-Pacific: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 283 Rest of Asia-Pacific: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 284 Rest of Asia-Pacific: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 285 Middle East & Africa: Digital Biomarkers Market, by Country, 2024-2031 (USD Million)
Table 286 Middle East & Africa: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 287 Middle East & Africa: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 288 Middle East & Africa: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 289 Middle East & Africa: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 290 Middle East & Africa: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 291 Middle East & Africa: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 292 Middle East & Africa: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 293 Middle East & Africa: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 294 Middle East & Africa: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 295 Gcc Countries: Digital Biomarkers Market, by Country, 2024-2031 (USD Million)
Table 296 Gcc Countries: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 297 Gcc Countries: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 298 Gcc Countries: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 299 Gcc Countries: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 300 Gcc Countries: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 301 Gcc Countries: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 302 Gcc Countries: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 303 Gcc Countries: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 304 Gcc Countries: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 305 Saudi Arabia: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 306 Saudi Arabia: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 307 Saudi Arabia: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 308 Saudi Arabia: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 309 Saudi Arabia: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 310 Saudi Arabia: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 311 Saudi Arabia: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 312 Saudi Arabia: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 313 Saudi Arabia: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 314 Uae: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 315 Uae: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 316 Uae: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 317 Uae: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 318 Uae: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 319 Uae: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 320 Uae: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 321 Uae: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 322 Uae: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 323 Other Gcc Countries: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 324 Other Gcc Countries: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 325 Other Gcc Countries: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 326 Other Gcc Countries: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 327 Other Gcc Countries: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 328 Other Gcc Countries: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 329 Other Gcc Countries: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 330 Other Gcc Countries: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 331 Other Gcc Countries: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 332 South Africa: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 333 South Africa: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 334 South Africa: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 335 South Africa: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 336 South Africa: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 337 South Africa: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 338 South Africa: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 339 South Africa: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 340 South Africa: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 341 Rest of Middle East & Africa: Digital Biomarkers Market, by Type, 2024-2031 (USD Million)
Table 342 Rest of Middle East & Africa: Digital Biomarkers Market, by Therapeutic Area, 2024-2031 (USD Million)
Table 343 Rest of Middle East & Africa: Digital Biomarkers Market for Cardiovascular, by Condition, 2024-2031 (USD Million)
Table 344 Rest of Middle East & Africa: Digital Biomarkers Market for Oncology, by Tumor Type, 2024-2031 (USD Million)
Table 345 Rest of Middle East & Africa: Digital Biomarkers Market for Solid Tumors, by Type, 2024-2031 (USD Million)
Table 346 Rest of Middle East & Africa: Digital Biomarkers Market for Hematologic Malignancies, by Type, 2024-2031 (USD Million)
Table 347 Rest of Middle East & Africa: Digital Biomarkers Market, by Application, 2024-2031 (USD Million)
Table 348 Rest of Middle East & Africa: Digital Biomarkers Market for Clinical Research, by Phase, 2024-2031 (USD Million)
Table 349 Rest of Middle East & Africa: Digital Biomarkers Market, by End-user, 2024-2031 (USD Million)
Table 350 Overview of Strategies Adopted by Key Players in Digital Biomarkers Market, January 2022-March 2026
Table 351 Digital Biomarkers Market: Degree of Competition
Table 352 Digital Biomarkers Market: Region Footprint (14 Companies)
Table 353 Digital Biomarkers Market: Type Footprint (14 Companies)
Table 354 Digital Biomarkers Market: Therapeutic Area Footprint (14 Companies)
Table 355 Digital Biomarkers Market: Application Footprint (14 Companies)
Table 356 Digital Biomarkers Market: End-user Footprint (14 Companies)
Table 357 Digital Biomarkers Market: Detailed List of Key Startups/SMEs
Table 358 Digital Biomarkers Market: Competitive Benchmarking of Startups/SMEs, by Region
Table 359 Digital Biomarkers Market: Competitive Benchmarking of Startups/SMEs, by Type
Table 360 Digital Biomarkers Market: Product/Service Launches & Approvals, January 2022-March 2026
Table 361 Digital Biomarkers Market: Deals, January 2022-March 2026
Table 362 Digital Biomarkers Market: Other Developments, January 2022-March 2026
Table 363 Ixico PLC: Company Overview
Table 364 Ixico PLC: Products Offered
Table 365 Ixico PLC.: Product Launches/Approvals, January 2022-March 2026
Table 366 Ixico PLC.: Deals, January 2022-March 2026
Table 367 Ametris, LLC: Company Overview
Table 368 Ametris LLC: Products Offered
Table 369 Ametris LLC: Product Launches/Enhancements, January 2022-March 2026
Table 370 Ametris, LLC: Deals, January 2022-March 2026
Table 371 Empatica Inc.: Company Overview
Table 372 Empatica Inc.: Products/Solutions Offered
Table 373 Empatica Inc.: Product Launches/Approvals, January 2022-March 2026
Table 374 Empatica Inc.: Deals, January 2022-March 2026
Table 375 Alivecor, Inc.: Company Overview
Table 376 Alivecor, Inc.: Products Offered
Table 377 Alivecor, Inc.: Product Launches/Approvals, January 2022-March 2026
Table 378 Alivecor, Inc.: Deals, January 2022-March 2026
Table 379 Conneqt Health: Company Overview
Table 380 Conneqt Health: Products Offered
Table 381 Conneqt Health: Product Enhancements/Approvals, January 2022-March 2026
Table 382 Vivosense: Company Overview
Table 383 Vivosense: Products Offered
Table 384 Vivosense: Other Developments, January 2022-March 2026
Table 385 Biosensics: Company Overview
Table 386 Biosensics: Products Offered
Table 387 Biosensics: Product Launches/Approvals, January 2022-March 2026
Table 388 Biosensics: Deals, January 2022-March 2026
Table 389 Lunit Inc.: Company Overview
Table 390 Lunit Inc.: Products Offered
Table 391 Lunit Inc.: Product Launches/Approvals, January 2022-March 2026
Table 392 Lunit Inc.: Deals, January 2022-March 2026
Table 393 Akili, Inc.: Company Overview
Table 394 Akili, Inc.: Products Offered
Table 395 Akili, Inc.: Deals, January 2022-March 2026
Table 396 Quibim: Company Overview
Table 397 Quibim: Products Offered
Table 398 Quibim: Product Launches/Approvals/Enhancements, January 2022-March 2026
Table 399 Quibim: Deals, January 2022-March 2026
Table 400 Clario: Company Overview
Table 401 Clario: Products Offered
Table 402 Clario: Deals, January 2022-March 2026
Table 403 Proscia Inc.: Company Overview
Table 404 Proscia Inc.: Products Offered
Table 405 Proscia Inc.: Product Launches/Approvals, January 2022-March 2026
Table 406 Proscia Inc.: Deals, January 2022-March 2026
Table 407 Koneksa Health: Company Overview
Table 408 Koneksa Health: Products Offered
Table 409 Koneksa Health: Product Launches, January 2022-March 2026
Table 410 Koneksa Health: Deals, January 2022- March 2026
Table 411 Linus Health: Company Overview
Table 412 Linus Health: Products Offered
Table 413 Linus Health: Product Launches/Approvals, January 2022-March 2026
Table 414 Linus Health: Deals, January 2022-March 2026
Table 415 Sonde Health, Inc.: Company Overview
Table 416 Altoida: Company Overview
Table 417 Imvaria Inc.: Company Overview
Table 418 Cumulus Neuroscience Limited: Company Overview
Table 419 Delve Health: Company Overview
Table 420 Feel Therapeutics: Company Overview
Table 421 Nanowear Inc.: Company Overview
Table 422 Exosystems: Company Overview
Table 423 Cardiosignal: Company Overview
Table 424 Imagene AI Ltd.: Company Overview
Table 425 Neurotrack Technologies, Inc.: Company Overview
Table 426 Risk Assessment: Digital Biomarkers Market

Figure 1 Digital Biomarkers Market Segmentation
Figure 2 Market Scenario
Figure 3 Global Digital Biomarkers Market, 2024-2031
Figure 4 Major Strategies Adopted by Key Players in Digital Biomarkers Market, 2023-2026
Figure 5 Disruptions Influencing Growth of Digital Biomarkers Market
Figure 6 High-Growth Segments in Digital Biomarkers Market, 2026-2031
Figure 7 Asia-Pacific to Register Highest CAGR in Digital Biomarkers Market During Forecast Period
Figure 8 Rising in Clinical Trial Volumes to Drive Growth in Digital Biomarkers Market
Figure 9 Clinical Research Applications Accounted for Largest Market Share in North America in 2025
Figure 10 India to Register Highest Growth Rate During Forecast Period
Figure 11 Digital Biomarkers Market: Porter's Five Forces Analysis
Figure 12 Digital Biomarkers Market: Supply Chain Analysis
Figure 13 Digital Biomarkers Market: Ecosystem Analysis
Figure 14 Trends/Disruptions Impacting Customers’ Businesses
Figure 16 Influence of Stakeholders on Buying Process for End-users
Figure 17 Key Buying Criteria for Top Three End-users
Figure 18 Digital Biomarkers Market: Patent Publication Trends, 2015-2026
Figure 19 Digital Biomarkers Market: Jurisdiction and Top Applicant Analysis
Figure 20 Digital Biomarkers Market: Top Applicants & Owners (Companies/Institutions), January 2015-April 2026
Figure 21 Market Potential of AI/Gen AI on Digital Biomarkers Across Industries
Figure 22 Impact of AI/Gen AI on Interconnected and Adjacent Ecosystems
Figure 23 Trial Phases with Digital Endpoints
Figure 24 North America: Digital Biomarkers Market Snapshot
Figure 25 Asia-Pacific: Digital Biomarkers Market Snapshot
Figure 26 Digital Biomarkers Market: Revenue Analysis of Key Players
Figure 27 Digital Biomarkers Market Share Analysis of Key Players (2025)
Figure 28 Digital Biomarkers Market: Brand Comparative Analysis
Figure 29 EV/Ebitda of Key Vendors
Figure 30 Year-To-Date (Ytd) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 31 Digital Biomarkers Market: Company Evaluation Matrix (2025)
Figure 32 Digital Biomarkers Market: Company Footprint
Figure 33 Digital Biomarkers Market: Company Evaluation Matrix (Startups/SMEs), 2025
Figure 34 Ixico PLC: Company Snapshot (2025)
Figure 35 Conneqt Health: Company Snapshot (2025)
Figure 36 Lunit Inc.: Company Snapshot (2025)
Figure 37 Research Design
Figure 38 Breakdown of Primary Interviews: by Company Type, Designation, and Region
Figure 39 Research Methodology: Hypothesis Building
Figure 40 Bottom-Up Approach
Figure 41 Top-Down Approach
Figure 42 CAGR Projections Based on Droc Analysis of Digital Biomarkers Industry
Figure 43 CAGR Projections: Supply-Side Analysis
Figure 44 Data Triangulation Methodology